Cargando…
Sodium-glucose co-transporter 2 inhibitor empagliflozin inhibits the cardiac Na(+)/H(+) exchanger 1: persistent inhibition under various experimental conditions
Autores principales: | Zuurbier, Coert J, Baartscheer, Antonius, Schumacher, Cees A, Fiolet, Jan W T, Coronel, Ruben |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683702/ https://www.ncbi.nlm.nih.gov/pubmed/33792689 http://dx.doi.org/10.1093/cvr/cvab129 |
Ejemplares similares
-
Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits
por: Baartscheer, Antonius, et al.
Publicado: (2016) -
The Driving Force of the Na(+)/Ca(2+)-Exchanger during Metabolic Inhibition
por: Baartscheer, Antonius, et al.
Publicado: (2011) -
Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells
por: Chen, Sha, et al.
Publicado: (2023) -
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation
por: Uthman, Laween, et al.
Publicado: (2017) -
Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
por: Uthman, Laween, et al.
Publicado: (2018)